ClinicalTrials.gg
Active, not recruitingNCT06196840Updated Mar 6, 2026

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

A Phase 2 interventional study of LX102 subretinal injection and Aflibercept intravitreal injection in Neovascular Age-Related Macular Degeneration, sponsored by Innostellar Biotherapeutics Co.,Ltd. Active, not recruiting at 11 sites in China. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Innostellar Biotherapeutics Co.,Ltd · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
50 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
50th of 91
50 · median 62
Started
2024
with 6 others
Phase 2
14 of 107
4 open now
Primary completion
2025-06
later than 5 of 42 live
Registered
74th of 107
by date
Lead sponsor
3 of 107
Innostellar Biotherapeutics Co.,Ltd

Among the 107 studies in Macular Degeneration with a site in China, this one is the 50th largest by planned enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2024, is one of 14 in phase 2, reaches primary completion later than 5 of the 42 other live ones, and was the 74th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.

Read the detailed description

In this Phase 2, multi-center, randomized controlled study, subjects will be randomized to receive one of the two dose levels of LX102 (n=20 for each dose level), or aflibercept (n=10).

Safety, tolerability, and efficacy will be evaluated for a period of approximately 1 year from baseline.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration

Keywords

  • Age-related macular degeneration
  • AMD
  • Neovascular AMD
  • Neovascular age-related macular degeneration
04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the , and willing to attend follow-up visits.
  2. Age ≥ 50, and ≤ 89.
  3. Diagnosis of active CNV secondary to neovascular AMD.
  4. BCVA ETDRS letters between 19 and 73.
  5. Demonstrated a meaningful response to anti-VEGF therapy.

Exclusion criteria

Exclusion Criteria:

  1. CNV or macular edema in the study eye secondary to diseases other than nAMD.
  2. Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement.
  3. Absence of RPE tear at Screening.
  4. Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, in the last 6 months.
  5. Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg.
  6. Uncontrolled diabetes defined as >8.0%.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    LX102 Dose 1

    LX102 will be administered at the assigned dose level as a single dose subretinal injection on Day 0

    Genetic: LX102 subretinal injection

  • Experimental
    LX102 Dose 2

    LX102 will be administered at the assigned dose level as a single dose subretinal injection on Day 0

    Genetic: LX102 subretinal injection

  • Active comparator
    Control group

    Aflibercept at a fixed regimen will be administered.

    Biological: Aflibercept intravitreal injection

Interventions

  • GeneticLX102 subretinal injection

    LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

  • BiologicalAflibercept intravitreal injection

    Commercially available Active Comparator

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in Best Corrected Visual Acuity (BCVA)

    BCVA measured by ETDRS

    Time frame: 36 weeks

Secondary outcomes

  1. Mean change from baseline in Best Corrected Visual Acuity (BCVA)

    BCVA measured by ETDRS

    Time frame: 52 weeks

  2. Mean change in Central Subfield Thickness (CST) from Baseline

    CST measured by spectral domain optical coherence tomography (SD-OCT)

    Time frame: 36 weeks, 52 weeks

  3. Durability of LX102 treatment

    Mean time from LX102 administration to anti-VEGF rescue injection for the first time, percentage of participants requiring anti-VEGF rescue injection, and mean number of anti-VEGF rescue injections through 52 weeks following LX102 administration.

    Time frame: 52 weeks

  4. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Incidence of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following LX102 subretinal injection

    Time frame: 36 weeks, 52 weeks

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jun 2025, 17 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 17 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2023
First posted
Jan 9, 2024
StartActual
Jan 24, 2024
Primary completionActual
Jun 24, 2025
CompletionEst.
Oct 2029
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06196840
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Jan 24, 2024
Primary completion
Jun 24, 2025
Completion
Oct 2029 (estimated)
Last update
Mar 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion